Loading clinical trials...
Loading clinical trials...
A Phase 3, Long-term, Open-label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
The objective of this study is to evaluate the long-term safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with Major Depressive Disorder (MDD).
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Forest Investigative Site 032
Tucson, Arizona, United States
Forest Investigative Site 109
Tucson, Arizona, United States
Forest Investigative Site 105
Fayetteville, Arkansas, United States
Forest Investigative Site 018
Little Rock, Arkansas, United States
Forest Investigative Site 029
Little Rock, Arkansas, United States
Forest Investigative Site 082
Garden Grove, California, United States
Forest Investigative Site 107
Long Beach, California, United States
Forest Investigative Site 104
National City, California, United States
Forest Investigative Site 022
Newport Beach, California, United States
Forest Investigative Site 004
Oceanside, California, United States
Start Date
April 29, 2013
Primary Completion Date
July 27, 2015
Completion Date
July 27, 2015
Last Updated
August 21, 2019
442
ACTUAL participants
Cariprazine
DRUG
Antidepressant Therapy (ADT)
DRUG
Lead Sponsor
Forest Laboratories
Collaborators
NCT07115329
NCT06793397
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07025720